Verinurad is a Small Molecule owned by AstraZeneca, and is involved in 20 clinical trials, which were completed.
Verinurad specifically binds to and inhibits URAT1, which is responsible for the regulation of uric acid levels in kidney. URAT1 mediates the reabsorption of uric acid, thereby regulating blood uric acid concentrations. The drug candidate inhibits the re-absorption of uric acid at the proximal convoluted tubule by facilitating urinary excretion of uric acid and decreasing plasma urate concentrations which is done through inhibition of the urate anion transporter.
The revenue for Verinurad is expected to reach a total of $91m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Verinurad NPV Report.
Verinurad (RDEA-3170) is under development for the treatment of chronic kidney disease with preserved ejection fraction and hyperuricemia. It is administered by orally as a capsule. It is a next-generation inhibitor of the URAT1 transporter. It was under development for gout and hyperuricaemia, heart failure. It is a new molecular entity (NME).
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.
Quick View – Verinurad
|Highest Development Stage|